Last Update 07 May 26
Fair value Decreased 7.13%BRO: Ongoing Buybacks And Solid Margins Will Support Future Upside
Analysts have trimmed their price target for Brown & Brown to about $73.80, down from around $79.47, as they now apply a slightly higher discount rate and assume more moderate revenue growth, profit margins, and future P/E levels.
What's in the News
- From October 1, 2025 to December 31, 2025, Brown & Brown repurchased 1,255,970 shares for US$100 million, representing 0.37% of the company. (Key Developments)
- Under the share repurchase program announced on July 20, 2015, Brown & Brown has completed total buybacks of 17,785,072 shares for US$622.96 million, representing 6.26% of the company. (Key Developments)
Valuation Changes
- Fair Value: updated to $73.80 from $79.47, a modest reduction in the implied share value.
- Discount Rate: adjusted slightly higher to 7.11% from 6.98%, reflecting a marginally higher required return.
- Revenue Growth: trimmed to 9.25% from 11.99%, pointing to more moderate dollar revenue expectations.
- Net Profit Margin: eased to 16.69% from 17.46%, indicating slightly lower projected profitability.
- Future P/E: revised to 27.64x from 28.71x, suggesting a small contraction in the valuation multiple applied.
Key Takeaways
- Strategic acquisitions and proactive market management could enhance revenue streams and stabilize opportunities, supporting sustained growth and expanded market presence.
- Effective cost management and debt strategies, coupled with strong cash flow, position Brown & Brown to increase earnings stability amidst economic uncertainties.
- Economic and legislative uncertainties, along with rising costs and lower-than-expected revenue growth, may pressure Brown & Brown's earnings and net margins across multiple segments.
Catalysts
About Brown & Brown- Brown & Brown, Inc. markets and sells insurance products and services in the United States, Canada, Ireland, the United Kingdom, and internationally.
- Brown & Brown's strategic focus on acquisitions, having completed 13 acquisitions with projected annual revenues of $36 million, could significantly enhance future revenue streams and market presence. This aligns with their goal of sustained revenue growth through expansion.
- The company's effective cost management and debt repayment strategies have led to reduced interest expenses and an improved EBITDAC margin by 110 basis points. This focus on managing financial liabilities could enhance future net margins and earnings.
- The ongoing demand for employee benefits consulting, driven by rising medical and pharmacy costs, suggests potential for continued revenue growth in this high-demand area, which can positively impact overall revenue and margins.
- Brown & Brown's proactive approach in the CAT property market, including anticipated rate reductions, allows them to strategically manage and capture opportunities in this volatile segment, potentially stabilizing and optimizing revenue from this line.
- Strong cash flow from operations, combined with a strategic focus on leveraging a diversified portfolio across geographies and lines of business, positions the company to navigate economic uncertainties and potentially increase future earnings stability and growth.
Brown & Brown Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Brown & Brown's revenue will grow by 9.3% annually over the next 3 years.
- Analysts assume that profit margins will shrink from 18.2% today to 16.7% in 3 years time.
- Analysts expect earnings to reach $1.4 billion (and earnings per share of $3.92) by about May 2029, up from $1.1 billion today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.7x on those 2029 earnings, up from 16.9x today. This future PE is greater than the current PE for the US Insurance industry at 11.4x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Uncertainty related to tariffs, inflation, and interest rates could lead business leaders to be more cautious and potentially defer projects, impacting overall economic expansion and future revenue growth.
- The decrease in CAT property rates due to excess capital could reduce the revenue generated from these lines, putting downward pressure on earnings in segments heavily reliant on CAT property.
- Pharmacy costs rising faster than medical costs may drive up expenses in employee benefits segments, potentially squeezing net margins if the costs cannot be fully passed on to customers.
- The anticipated decline in flood claim revenues in the fourth quarter due to a calmer hurricane season could result in lower-than-expected revenue growth in the Programs segment.
- Legislative changes, such as efforts to reverse Florida's insurance reforms, could create legal uncertainties and potentially increase liability costs, impacting the net margins of operations within the state.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $73.8 for Brown & Brown based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $90.0, and the most bearish reporting a price target of just $65.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $8.2 billion, earnings will come to $1.4 billion, and it would be trading on a PE ratio of 27.7x, assuming you use a discount rate of 7.1%.
- Given the current share price of $56.56, the analyst price target of $73.8 is 23.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Brown & Brown?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.